Danielle M Crookes1, Ryan T Demmer1, Katherine M Keyes1, Karestan C Koenen2, Shakira F Suglia1,3. 1. From the Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY. 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA. 3. Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Abstract
BACKGROUND: Among adults, depressive symptoms are associated with higher rates of cardiovascular disease; however, the evidence is mixed regarding the association between depressive symptoms and hypertension, especially among young adults. The deleterious effects of some antidepressant medications on blood pressure may contribute to mixed findings. METHODS: Adolescents enrolled in Add Health (N = 11,183) (1994-2008) completed an abbreviated Center for Epidemiologic Studies Depression Scale at three waves (mean ages, 16, 22, and 29). Antidepressant use was measured at age 22 and at age 29. Hypertension at age 29 was defined as measured systolic blood pressure of 140 mm Hg or greater, diastolic blood pressure of 90 mm Hg or greater, or staff-inventoried anti-hypertensive medication use. RESULTS: The prevalence of hypertension at age 29 was 20%. High depressive symptoms in adolescence or young adulthood were not associated with hypertension in young adulthood. Antidepressant use at age 29 was associated with increased prevalence of hypertension (prevalence ratio [PR], 1.4; 95% CI, 1.2, 1.7) and an interaction with sex was observed (PRMen, 1.6; 95% CI, 1.2, 2.0; PRWomen, 1.2; 95% CI, 0.89, 1.6; pinteraction = 0.0227). Selective serotonin reuptake inhibitor and non-selective serotonin reuptake inhibitor antidepressant use were associated with hypertension (PRSSRI, 1.3; 95% CI, 1.0, 1.6; PRnon-SSRI, 1.6; 95% CI, 1.2, 2.1). CONCLUSIONS: In this sample, antidepressant use, but not depressive symptoms, was associated with hypertension in young adulthood. Further research is recommended to examine joint and independent relationships between depression and antidepressant use and hypertension among young adults. See video abstract at, http://links.lww.com/EDE/B355.
BACKGROUND: Among adults, depressive symptoms are associated with higher rates of cardiovascular disease; however, the evidence is mixed regarding the association between depressive symptoms and hypertension, especially among young adults. The deleterious effects of some antidepressant medications on blood pressure may contribute to mixed findings. METHODS: Adolescents enrolled in Add Health (N = 11,183) (1994-2008) completed an abbreviated Center for Epidemiologic Studies Depression Scale at three waves (mean ages, 16, 22, and 29). Antidepressant use was measured at age 22 and at age 29. Hypertension at age 29 was defined as measured systolic blood pressure of 140 mm Hg or greater, diastolic blood pressure of 90 mm Hg or greater, or staff-inventoried anti-hypertensive medication use. RESULTS: The prevalence of hypertension at age 29 was 20%. High depressive symptoms in adolescence or young adulthood were not associated with hypertension in young adulthood. Antidepressant use at age 29 was associated with increased prevalence of hypertension (prevalence ratio [PR], 1.4; 95% CI, 1.2, 1.7) and an interaction with sex was observed (PRMen, 1.6; 95% CI, 1.2, 2.0; PRWomen, 1.2; 95% CI, 0.89, 1.6; pinteraction = 0.0227). Selective serotonin reuptake inhibitor and non-selective serotonin reuptake inhibitor antidepressant use were associated with hypertension (PRSSRI, 1.3; 95% CI, 1.0, 1.6; PRnon-SSRI, 1.6; 95% CI, 1.2, 2.1). CONCLUSIONS: In this sample, antidepressant use, but not depressive symptoms, was associated with hypertension in young adulthood. Further research is recommended to examine joint and independent relationships between depression and antidepressant use and hypertension among young adults. See video abstract at, http://links.lww.com/EDE/B355.
Authors: Lijing L Yan; Kiang Liu; Karen A Matthews; Martha L Daviglus; T Freeman Ferguson; Catarina I Kiefe Journal: JAMA Date: 2003-10-22 Impact factor: 56.272
Authors: Dan J Stein; Sergio Aguilar-Gaxiola; Jordi Alonso; Ronny Bruffaerts; Peter de Jonge; Zharoui Liu; Jose Miguel Caldas-de-Almeida; Siobhan O'Neill; Maria Carmen Viana; Ali Obaid Al-Hamzawi; Mattias C Angermeyer; Corina Benjet; Ron de Graaf; Finola Ferry; Viviane Kovess-Masfety; Daphna Levinson; Giovanni de Girolamo; Silvia Florescu; Chiyi Hu; Norito Kawakami; Josep Maria Haro; Marina Piazza; Jose Posada-Villa; Bogdan J Wojtyniak; Miguel Xavier; Carmen C W Lim; Ronald C Kessler; Kate M Scott Journal: Gen Hosp Psychiatry Date: 2013-11-14 Impact factor: 3.238
Authors: Benjamin I Goldstein; Mercedes R Carnethon; Karen A Matthews; Roger S McIntyre; Gregory E Miller; Geetha Raghuveer; Catherine M Stoney; Hank Wasiak; Brian W McCrindle Journal: Circulation Date: 2015-08-10 Impact factor: 29.690
Authors: Amit J Shah; Nima Ghasemzadeh; Elisa Zaragoza-Macias; Riyaz Patel; Danny J Eapen; Ian J Neeland; Pratik M Pimple; A Maziar Zafari; Arshed A Quyyumi; Viola Vaccarino Journal: J Am Heart Assoc Date: 2014-06-18 Impact factor: 5.501
Authors: Nicholas Graham; Joey Ward; Daniel Mackay; J P Pell; Jonathan Cavanagh; Sandosh Padmanabhan; Daniel J Smith Journal: BMJ Open Date: 2019-09-30 Impact factor: 2.692
Authors: Ju Eun Lee; David Walton; Colleen P O'Connor; Michael Wammes; Jeremy P Burton; Elizabeth A Osuch Journal: Int J Mol Sci Date: 2022-06-14 Impact factor: 6.208